Enzalutamide and Leuprolide Acetate in Non-Metastatic Hormone-Sensitive Prostate Cancer: The Sooner the Better?
Future Oncology · 2024
DOI: 10.2217/fon-2023-1019 ↗Kurz gefasst
Editorial in der Zeitschrift Future Oncology, 2024. Verfasst von Emilio Francesco Giunta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Meldola, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Meldola, Italy.
- Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
ORCID-Profile: Emilio Francesco Giunta, Ugo De Giorgi
Zitieren
APA
Giunta, E. F., Gasperoni, L., & De Giorgi, U. (2024). Enzalutamide and Leuprolide Acetate in Non-Metastatic Hormone-Sensitive Prostate Cancer: The Sooner the Better?. Future Oncology. https://doi.org/10.2217/fon-2023-1019
Vancouver
Giunta EF, Gasperoni L, De Giorgi U. Enzalutamide and Leuprolide Acetate in Non-Metastatic Hormone-Sensitive Prostate Cancer: The Sooner the Better?. Future Oncology. 2024. doi:10.2217/fon-2023-1019
BibTeX
@article{Giunta2024,
author = {Giunta, Emilio Francesco and Gasperoni, Lorenzo and De Giorgi, Ugo},
title = {Enzalutamide and Leuprolide Acetate in Non-Metastatic Hormone-Sensitive Prostate Cancer: The Sooner the Better?},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-1019}
}
EUVIMED